Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) is a biopharmaceutical company developing innovative-targeted treatments for patients with cancer who do not have successful therapy choices.

Key Highlights:

• The company is yet to report any revenue from its operations.
• The company's net loss in Q3FY21 was USD 6.42 million, compared to USD 5.54 million in Q3FY20. Since its beginning, the company has incurred net losses, and the prospects aren't looking promising due to a lack of commercial revenues.
• The company is constantly issuing common stock and warrants, diluting existing shareholders' holdings and reducing their ownership in the company.
• Stock is currently trading below its crucial short-term as well as long-term 50-day and 200-day DMA support levels, a bearish indicator.
• Stock is currently leaning towards the lower end of the 52-week range of USD 4.91 to USD 10.30.
• ATNM's share price has declined 34.98% and 21.71% in the past three and six months, respectively.

Three-Year Technical Price Chart (as of January 31, 2022). Analysis by Kalkine Group

Conclusion: The company has not reported any revenues to date. Given the unstable fundamentals, lack of clarity in top-line growth, and bleak outlook, we recommend an "Avoid" rating on the stock at the closing price of USD 5.41, up 3.43%, as of January 31, 2022.

*The reference data in this report has been partly sourced from REFINITIV.

BioSig Technologies, Inc.

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device firm in the commercial stage. It works on a unique technological platform to reduce cardiac recordings' noise and artefacts during electrophysiology research and ablation.

Key Highlights:

• The company has just made USD 100 thousand in Q3FY21 vs. nil revenues in Q3FY20.
• The company has posted an operating loss of USD 7.80 million in Q3FY21 vs. USD 13.10 million in Q3FY20.
• As a loss-making enterprise, the company has generated negative EBITDA, operating, and net margins compared to positive industry margins.
• Stock is currently trading below its crucial short-term as well as long-term 50-day and 200-day DMA support levels, a bearish indicator.
• Stock is currently leaning towards the lower end of the 52-week range of USD 1.47 to USD 5.77.
• BSGM's share price has declined 45.23% and 49.43% in the past three and six months, respectively.

Three-Year Technical Price Chart (as of January 31, 2022). Analysis by Kalkine Group

Conclusion: The company has recently started its commercial sales. Given the wobbly fundamentals, lackluster top-line, and gloomy outlook, we recommend an "Avoid" rating on the stock at the closing price of USD 1.78, up 7.88%, as of January 31, 2022.

* The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.